Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
Healthcare Heroes: 3 Stocks Innovating in Medicine and Wellness
05:31pm, Wednesday, 27'th Dec 2023
The United States leads globally in the healthcare sector, with its innovative healthcare stocks drawing attention from an impressive $4.3 trillion in spending. As the American Medical Association hig
The Next Bull Run: 3 Stocks Poised for Unprecedented Growth in 2024
12:26pm, Wednesday, 27'th Dec 2023
In the dynamic retail and pharma space, the quest for identifying key stocks with promising growth potential is ever-present. Delving into the fundamentals of three corporate giants reveals a strategi
Moderna and Pfizer Stock Tumbled in 2023. Wall Street Sees a Rebound.
11:47am, Wednesday, 27'th Dec 2023
Covid-19-vaccine makers Moderna and Pfizer saw shares drop in 2023, but analysts expect double-digit-percentage gains next year.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
10:31am, Wednesday, 27'th Dec 2023
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase
09:00am, Tuesday, 26'th Dec 2023
Pfizer's stock has declined by -44.6% in 2023, but there may be an opportunity for long-term investors due to its current valuation. Pfizer's financials show that it is still profitable and has a stro
Top 3 Healthcare Stock Picks for the New Year
08:14pm, Monday, 25'th Dec 2023
After lagging most sectors in 2023, healthcare stocks could deliver substantial returns in 2024. The market has been overly pessimistic about the sector due to short-term challenges.
3 Blue-Chip Stocks Set for a 50% Surge in the Coming Year
05:16am, Monday, 25'th Dec 2023
In general, when we talk about 50% to 100% returns in a year, it's associated with growth stocks. However, there are instances where blue-chip stocks outperform backed by valuation factors or some maj
ChatGPT picks 5 stocks to buy for start of 2024
04:15am, Monday, 25'th Dec 2023
Despite the still-present threat of a recession and the relatively high inflation, 2023 – and especially its later months – brought respite to investors and created room for renewed optimism.
6 Reasons to Avoid Johnson & Johnson (JNJ) At All Costs
10:26am, Sunday, 24'th Dec 2023
Sponsored: Tips for Investing A financial advisor can help you understand the advantages and disadvantages of investment properties.
Are Investors Overreacting to Pfizer's Underwhelming Forecast for 2024?
08:15am, Saturday, 23'rd Dec 2023
Pfizer is going to see its business slow down next year as the pandemic fades further. If not for its recent acquisition of Seagen, the company's top line would struggle even more in 2024.
November Readers Noted 27 Ideal-To-Buy Dividend Dogs
02:38pm, Friday, 22'nd Dec 2023
I discuss reader feedback and suggestions regarding the author's daily stock lists and dividend investing strategies. I also address criticisms of preference for low-priced stocks and the debate over
5 Biotech Acquisition Targets To Accumulate In 2024
01:05pm, Thursday, 21'st Dec 2023
5 Biotech Acquisition Targets To Accumulate In 2024
The Top Healthcare Stocks to Buy With $100
10:07am, Thursday, 21'st Dec 2023
Pfizer has important, ongoing projects that should start to pay off down the road. Doximity's strong margins, moat, and growth opportunities could mean a bright future.
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
09:45am, Thursday, 21'st Dec 2023
The anti-obesity drug market could be a significant growth opportunity for healthcare companies. Eli Lilly and Novo Nordisk are the big names in the market today, but there could soon be others.
Dividend Harvesting Portfolio Week 146: $14,600 Allocated, $1,291.18 In Projected Dividends
09:00am, Thursday, 21'st Dec 2023
The Fed was more dovish than expected, discussing future target rates and leaving the door open for an additional rate hike if needed. The Dividend Harvesting Portfolio finished up 7.53% on invested c
